STOCK TITAN

Neurogene: Samsara BioCapital reports 9% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Neurogene Inc. (NGNE) Schedule 13G/A reports beneficial ownership as of September 30, 2026, by Samsara BioCapital, L.P. of 1,804,197 shares (9.0%), Samsara Opportunity Fund, L.P. of 150,000 shares (0.7%), and Srinivas Akkaraju of 1,954,197 shares (9.7%).

The reported positions overlap: Akkaraju and the entities’ general partners share voting and dispositive power over fund-held securities, so the amounts are not additive. Samsara BioCapital, L.P.’s position includes 1,717,127 common shares and pre-funded warrants immediately exercisable for up to 87,070 common shares. The percentages are based on 20,011,382 common shares outstanding as of August 7, 2026, with the warrants counted for Samsara BioCapital, Samsara GP and Akkaraju. The reporting persons expressly disclaim status as a group.

Samsara BioCapital, L.P. beneficial ownership 1,804,197 shares As of September 30, 2026; 9.0% of the class
Samsara Opportunity Fund, L.P. beneficial ownership 150,000 shares As of September 30, 2026; 0.7% of the class
Srinivas Akkaraju beneficial ownership 1,954,197 shares As of September 30, 2026; 9.7% of the class
Samsara BioCapital, L.P. ownership percentage 9.0% As of September 30, 2026
Samsara Opportunity Fund, L.P. ownership percentage 0.7% As of September 30, 2026
Srinivas Akkaraju ownership percentage 9.7% As of September 30, 2026
Shares issuable under pre-funded warrants Up to 87,070 shares Immediately exercisable; included in Samsara BioCapital, L.P.’s reported beneficial ownership
Common shares outstanding 20,011,382 shares As of August 7, 2026; basis for the reported ownership percentages
beneficial ownership financial
"aggregate number of shares of common stock ... beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Pre-Funded Warrants financial
"pre-funded warrants ("Pre-Funded Warrants") immediately exercisable"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
shared voting power technical
"Shared Voting Power 1,804,197.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power technical
"Shared Dispositive Power 1,804,197.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NGNE shares did Samsara BioCapital report owning?

Samsara BioCapital, L.P. reported beneficial ownership of 1,804,197 shares as of September 30, 2026. That total includes 1,717,127 common shares and pre-funded warrants immediately exercisable for up to 87,070 common shares.

How much Neurogene stock did Srinivas Akkaraju beneficially own?

Srinivas Akkaraju reported beneficial ownership of 1,954,197 shares, or 9.7%, as of September 30, 2026. The filing states that he shares voting and dispositive power over securities held by Samsara BioCapital, L.P. and Samsara Opportunity Fund, L.P.

What share count did the NGNE ownership percentages use?

The reported percentages were based on 20,011,382 shares of Neurogene common stock outstanding as of August 7, 2026. The calculation gives effect to pre-funded warrants for Samsara BioCapital, L.P., Samsara BioCapital GP, LLC and Srinivas Akkaraju.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





64135M105

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Samsara BioCapital, L.P.
Signature:/s/ Srinivas Akkaraju
Name/Title:By Samsara BioCapital GP, LLC, its General Partner, By Srinivas Akkaraju, Managing Member
Date:11/16/2026
Samsara BioCapital GP, LLC
Signature:/s/ Srinivas Akkaraju
Name/Title:By Srinivas Akkaraju, Managing Member
Date:11/16/2026
Samsara Opportunity Fund, L.P.
Signature:/s/ Srinivas Akkaraju
Name/Title:By Samsara Opportunity Fund GP, LLC, its General Partner, By Srinivas Akkaraju, Managing Member
Date:11/16/2026
Samsara Opportunity Fund GP, LLC
Signature:/s/ Srinivas Akkaraju
Name/Title:By Srinivas Akkaraju, Managing Member
Date:10/16/2026
Srinivas Akkaraju
Signature:/s/ Srinivas Akkaraju
Name/Title:Srinivas Akkaraju
Date:11/16/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement

Keep reading